US Meeting Set For CBDs’ Impact On Pregnancies, Gender-Specific Biological, Psychosocial Effects
Executive Summary
FDA schedules public meeting for 19 November to discuss sex and gender differences in the use and response to cannabidiols. The meeting will address the issue of CBD use in pregnancy, for which no human data currently is available.
You may also be interested in...
Unpublished And Under Review? US FDA’s CBD Policy Draft Guidance Still Has Industry Talking
Supplements containing hemp-derived cannabidiols aren’t typical products subject to FDA’s regulatory oversight, and the document stating its thinking on enforcement in the market submitted to the Office of Management and Budget isn’t a typical draft guidance.
As A Botanical, Cannabidiol Was Next Ingredient Up For AHPA's Guidance On Use In Supplements
Leading discussions on CBD safety as a dietary ingredient and developing best-practices guidance were natural steps for AHPA. "We were viewing it as another botanical product, another one of the type of products that we’ve been dealing with throughout our history," said program development director Jane Wilson.
FDA Decision On CBD Use Could Run Up Against Chicken Or Egg Question
Speakers at FDA's first-ever public hearing on using cannabis-derived ingredients in products subject to its oversight asked agency officials to look back further than history of drug research with cannabinoids to earlier than the origin of its regulations as it considers its decision. "CBD is a constituent inherent in hemp which has been marketed and used at least since the Civil War," says cannabis business attorney Rob Kight.